

# 1 **Chromosome X-Wide Common Variant Association Study (XWAS) in Autism Spectrum** 2 **Disorder**

3 Marla Mendes<sup>\*1,2</sup>, Desmond Zeya Chen<sup>2,3</sup>, Worrawat Engchuan<sup>1,2</sup>, Thiago Peixoto Leal<sup>4</sup>,  
4 Bhooma Thiruvahindrapuram<sup>1,2</sup>, Brett Trost<sup>5,6</sup>, Jennifer L. Howe<sup>1,2</sup>, Giovanna Pellecchia<sup>1,2</sup>,  
5 Thomas Nalpathamkalam<sup>1,2</sup>, Roumiana Alexandrova<sup>1,2</sup>, Nelson Bautista Salazar<sup>1,2</sup>, Ethan  
6 Alexander McKee<sup>1,2</sup>, Natalia Rivera Alfaro<sup>1,2</sup>, Meng-Chuan Lai<sup>7,8,9</sup>, Sara Bandres-Ciga<sup>10</sup>,  
7 Delnaz Roshandel<sup>1,2</sup>, Clarrisa A. Bradley<sup>1,2</sup>, Evdokia Anagnostou<sup>11,12</sup>, Lei Sun<sup>3,13</sup>, Stephen W.  
8 Scherer<sup>\*1,2,6,14</sup>

## 9 **Affiliations**

10 1. The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, M5G  
11 0A4, Canada.

12 2. Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, ON,  
13 M5G 0A4, Canada.

14 3. Department of Statistical Sciences, Faculty of Arts and Science, University of Toronto,  
15 Toronto, ON, M5G 1X6, Canada.

16 4. Lerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, OH, 44106,  
17 USA

18 5. Molecular Medicine Program, The Hospital for Sick Children, Toronto, ON, M5G 0A4,  
19 Canada.

20 6. Department of Molecular Genetics, University of Toronto, Toronto, ON, M5S 1A8,  
21 Canada.

22 7. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental  
23 Health, Toronto, ON, M5G 2C1, Canada

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 8. Department of Psychiatry, The Hospital for Sick Children, Toronto, ON, M5G 1E8,  
25 Canada.

26 9. Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto,  
27 ON, M5T 1R8, Canada

28 10. Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda,  
29 MD, 20892, USA.

30 11. Autism Research Centre, Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON,  
31 M4G 1R8, Canada.

32 12. Institute of Medical Science, University of Toronto, Toronto, ON, M5S 1A8, Canada.

33 13. Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto,  
34 Toronto, ON, M5S 3E3, Canada.

35 14. McLaughlin Centre and Department of Molecular Genetics, University of Toronto,  
36 Toronto, ON, M5S 1A8, Canada.

37 \*Correspondence: [marla.mendesdeaquino@sickkids.ca](mailto:marla.mendesdeaquino@sickkids.ca)

38 \*Correspondence: [stephen.scherer@sickkids.ca](mailto:stephen.scherer@sickkids.ca)

### 39 **Abstract**

40 Autism Spectrum Disorder (ASD) displays a notable male bias in prevalence. Research into  
41 rare (<0.1) genetic variants on the X chromosome has implicated over 20 genes in ASD  
42 pathogenesis, such as *MECP2*, *DDX3X*, and *DMD*. The "female protective effect" in ASD  
43 suggests that females may require a higher genetic burden to manifest similar symptoms as  
44 males, yet the mechanisms remain unclear. Despite technological advances in genomics, the  
45 complexity of the biological nature of sex chromosomes leave them underrepresented in  
46 genome-wide studies. Here, we conducted an X chromosome-wide association study (XWAS)

47 using whole-genome sequencing data from 6,873 individuals with ASD (82% males) across  
48 Autism Speaks MSSNG, Simons Simplex Cohort SSC, and Simons Foundation Powering  
49 Autism Research SPARK, alongside 8,981 population controls (43% males). We analyzed  
50 418,652 X-chromosome variants, identifying 59 associated with ASD ( $p$ -values  $7.9 \times 10^{-6}$  to  
51  $1.51 \times 10^{-5}$ ), surpassing Bonferroni-corrected thresholds. Key findings include significant  
52 regions on chrXp22.2 (lead SNP=rs12687599,  $p=3.57 \times 10^{-7}$ ) harboring *ASB9/ASB11*, and  
53 another encompassing *DDX53/PTCHD1-AS* long non-coding RNA (lead SNP=rs5926125,  
54  $p=9.47 \times 10^{-6}$ ). When mapping genes within 10kb of the 59 most significantly associated SNPs,  
55 91 genes were found, 17 of which yielded association with ASD (*GRPR*, *AP1S2*, *DDX53*,  
56 *HDAC8*, *PCDH19*, *PTCHD1*, *PCDH11X*, *PTCHD1-AS*, *DMD*, *SYAP1*, *CNKSR2*, *GLRA2*,  
57 *OFD1*, *CDKL5*, *GPRASP2*, *NXF5*, *SH3KBP1*). *FGF13* emerged as a novel X-linked ASD  
58 candidate gene, highlighted by sex-specific differences in minor allele frequencies. These  
59 results reveal significant new insights into X chromosome biology in ASD, confirming and  
60 nominating genes and pathways for further investigation.

## 61 **1. Introduction**

62 Autism Spectrum Disorder (ASD [MIM 209850]) is a neurodevelopmental condition defined by  
63 social communication atypicalities, restrictive interests and repetitive sensory–motor  
64 behaviors. It is diagnosed in ~1% of the population worldwide<sup>1,2</sup>, with a 3-4:1 male:female  
65 prevalence ratio<sup>3,4</sup>.

66 This difference may have demographic and social components, with one example being that  
67 some autistic traits, such as restricted interests, may be more normalized in females compared  
68 with male individuals, and consequently ASD could be underdiagnosed<sup>5</sup>. However, there is  
69 evidence for a significant biological influence on the sex-differential likelihood of ASD<sup>6–11</sup>. For  
70 example, females with neurodevelopmental disorders, including ASD, tend to have an excess  
71 of deleterious autosomal copy number variants (CNVs), and deleterious autosomal single-  
72 nucleotide variants (SNVs)<sup>6,7,10–13</sup>. Variation in steroid hormones and differential gene

73 expression in males and females may also influence ASD likelihood and characteristics<sup>8</sup>.  
74 Another consideration, which may be influenced by the afore-mentioned observations, is that  
75 in a family with a son having ASD, the likelihood of a female sibling also being affected is 4.2%,  
76 a number that increases to 12.9% if the sib is male<sup>14</sup>.

77 Collectively the evidence may suggest a hypothetical "female protective effect" whereby  
78 females require a quantitatively greater etiologic load than males to exhibit the same degree  
79 of clinical presentation of ASD<sup>15-17</sup>. The sex ratio contribution approaches 1:1 when  
80 considering *de novo* mutations affecting presumed 'penetrant' autosomal genes and copy  
81 number variants (CNVs) in ASD and other neurodevelopmental conditions<sup>18-20</sup>. However,  
82 some studies suggest that the etiology of ASD includes qualitative sex differences, particularly  
83 involving genetic variations on the X chromosome.<sup>21</sup> Sex hormones, known influencers of  
84 typical male and female brain development<sup>22</sup>, may also contribute to sex-varied penetrance in  
85 ASD<sup>23</sup>. For example, a surge of testosterone in the male fetus, combined with XY  
86 chromosomal determinants, may impact the neuroimmune system, affecting dendritic  
87 arborization<sup>24</sup> and the number of microglia and neurons<sup>25</sup>, hence contribute to the sex-  
88 difference biology of ASD.


89 Currently, there are 23 SFARI<sup>26</sup> score 1 and 36 SFARI<sup>26</sup> score 2 genes with evidence to be  
90 involved in ASD mapping to the X chromosome<sup>26</sup>. Nine of these reach a sufficient "Evaluation  
91 of Autism Gene Link Evidence (EAGLE)" score to be considered definitively involved in more  
92 narrowly-defined ASD<sup>27</sup> (the SFARI and EAGLE genes are often used in diagnostic testing  
93 panels for ASD)<sup>28</sup>. Since upwards of 75% of genome-wide studies do not consider rare or  
94 common variants (including polygenic score analysis) on the sex chromosomes in their  
95 analysis<sup>29</sup>, it is anticipated there are additional gene loci to be validated and others to be  
96 discovered (Table S1 summarizes the published genome-wide manuscripts examining the X-  
97 chromosome). One study has attempted a genetic association test for ASD using common  
98 variants on the X chromosome<sup>30</sup>, finding *TBL1X* as a candidate locus (Table S1).

99 There are, however, complications in studying the X chromosome as it has a lower genetic  
100 diversity compared to the autosomes, because, apart from the small pseudoautosomal region,  
101 this genomic region does not recombine in males<sup>29</sup>. Thus, the X chromosome can be more  
102 sensitive to evolutionary events, such as sex-bias admixture, bottlenecks and natural selection,  
103 and it can have different mutation rates from autosomes<sup>31</sup>. Moreover, in females, the X-  
104 inactivation phenomenon can occur where a random X chromosome copy may be inactive (i.e.  
105 X chromosome dosage compensation)<sup>29,31,32</sup>. The issue of 50% reduced X-chromosome  
106 coverage in males (46XY) in microarray and sequencing experiments has also led to the  
107 understudy of this important sex chromosome<sup>29</sup>.

108 Recent development, however, now enables more robust X-wide association studies (XWAS)  
109 by dealing with X-specific quality control, statistical tests stratified by sex, estimation of  
110 significant thresholds, and accounting for the potential heterogeneity of allelic effect between  
111 males and females and chromosome inactivation bias<sup>29,33</sup>.

112 Here, we conducted a comprehensive XWAS of ASD from 6,873 ASD individuals (5,639 males  
113 and 1,234 females) sourced from three different whole-genome sequencing (WGS) datasets,  
114 alongside 8,981 control individuals (3,911 males and 5,070 females), from two additional  
115 datasets (Figure 1, Figure S1).

116 **2. Material and methods**



117

118 **Figure 1: XWAS workflow.** A) Outline of the XWAS pipeline detailing data sources including  
 119 MSSNG (Autism Speaks), SSC (Simons Simplex Cohort), SPARK (Simons Foundation  
 120 Powering Autism Research), 1KGP (1000 Genome Project), HostSeq (The Host Genome  
 121 Sequencing Initiative), and MGRB (Medical Genome Reference Bank). The significance  
 122 threshold was determined using Bonferroni correction, individually calculated for the Male-

123 XWAS, Female-XWAS, and Both-XWAS approaches. For Meta-XWAS, we used the threshold  
124 inferred from the Both-XWAS result. B) Replication and robustness studies conducted.

## 125 *2.1 Database*

### 126 *2.1.1. ASD Datasets*

127 The Autism Speaks MSSNG resource<sup>34,35</sup> is a dataset of genetic and phenotype information  
128 from individuals diagnosed with ASD as well as members of their families<sup>34,35</sup>. The affected  
129 individuals were diagnosed according to the Diagnostic and Statistical Manual of Mental  
130 Disorders (DSM)<sup>36</sup>, also supported in many individuals by the Autism Diagnostic Interview-  
131 Revised (ADI-R)<sup>37,38</sup> and/or the Autism Diagnostic Observation Schedule (ADOS)<sup>39,40</sup>. The  
132 Province of Ontario Neurodevelopmental Network (POND) is part of MSSNG and continues to  
133 contribute with new data. We used data from 9,621 individuals for the analysis done here.

134 The Simons Simplex Collection (SSC) includes WGS data from approximately 2,600 ASD  
135 simplex families (one affected child plus unaffected parents and siblings)<sup>41</sup>. The ASD  
136 diagnoses were performed following the University of Michigan Autism and Communication  
137 Disorders Center guidance to guarantee uniformity across the 12 university-affiliated research  
138 clinics involved in this initiative. We used 9,209 ASD participants from SSC in this analysis.  
139 Also from SFARI<sup>42</sup>, the SPARK data (Simons Foundation Powering Autism Research) is an  
140 autism research initiative that includes both WES (Whole Exome Sequence) and WGS data  
141 from US individuals, besides behaviour and phenotypic information. We used WGS from  
142 12,519 individuals for the X-chromosome analysis.

### 143 *2.1.2. Population/Control Datasets*

144 For ancestry inference, we used genetic information from 3,202 samples from 1000 Genomes  
145 Project of five different ancestries (Africans, Americans, East Asians, Europeans and South  
146 Asians). For this, we used the high-coverage 2020 version released by the New York Genome

147 Center (NYGC) ([https://www.internationalgenome.org/data-portal/data-collection/30x-](https://www.internationalgenome.org/data-portal/data-collection/30x-grch38)  
148 [grch38](https://www.internationalgenome.org/data-portal/data-collection/30x-grch38))<sup>43</sup>.

149 As ASD-controls we used data from 2,561 samples from the Medical Genome Reference Bank  
150 (MGRB)<sup>44</sup>, which is a WGS dataset from ~4,000 healthy, elderly Australians<sup>44</sup>. The MGRB  
151 dataset includes most individuals of European ancestry but does not exclude samples from  
152 different genetic backgrounds. We also used 9,802 samples from the Host Genome  
153 Sequencing Initiative (HostSeq)<sup>45</sup> which is a collection of 14 Canadian research studies  
154 examining responses to COVID-19.

## 155 *2.2 Quality Control*

### 156 2.2.1 Autosomes

157 After selecting biallelic variants we used the SmartQC software  
158 (<https://github.com/ldgh/MosaiQC-public>) to perform the basic control quality steps to remove:  
159 (i) variants with the chromosome notation equal to "0", (ii) remove variants with duplicated IDs,  
160 (iii) remove variants and samples with missing data greater than 10% (plink --geno 0.1; plink -  
161 -mind 0.1), (iv) impute sex codes using SNP data through PLINK's '--impute-sex --check-sex'  
162 functionality. (v) remove A|T and C|G variants (ambiguous SNPs), (vi) remove 100%  
163 heterozygous variants (plink --hardy) and (vii) annotate the variants for dbSNP ID and LiftOver  
164 for hg38 if necessary.

165 Using plink --bmerge, we merged the data from MSSNG, SSC, SPARK, MGRB, HostSeq. The  
166 merged file had a total of 22,242 samples and 1,407,803 variants (Figure 1, Figure S1).

167 For the XWAS analysis using Principal Components (PCs) based on the autosomal information  
168 as covariates for logistic regression, we cleaned our data based on the pipeline of Leal *et al*  
169 (2023)<sup>46</sup> (<https://github.com/MataLabCCF/XWAS>) in the merged file with MSSNG, SSC,  
170 SPARK, MGRB, and HostSeq. This cleaning pipeline adds the following steps; (i) removal of  
171 monomorphic SNPs, or those located in structural variants, using the list of SNPs located in



172 structural variants from Le Guen *et al.* (2021)<sup>32</sup> created using Tri-Typer<sup>47</sup>. (ii) remove of  
173 potential probe sites using gnomAD<sup>48</sup>, and (iii) relationship control using KING<sup>49</sup> to calculate  
174 the kinship coefficient and NAToRA<sup>50</sup> to remove samples with relatedness closer than second  
175 degree. After this XWAS cleaning pipeline the autosomal file had 1,075,065 SNPs and 21,089  
176 samples (Figure S1).

177 The final XWAS analysis was restricted to individuals with more than 75% European ancestry.  
178 To achieve this, we conducted an ancestry check utilizing ADMIXTURE software<sup>51</sup> with five  
179 clusters. The reference populations included Europeans, Africans, East Asians, South Asians,  
180 and Americans from the 1000 Genomes Project (1KGP)<sup>52</sup>. After merging our XWAS data with  
181 samples from the 1000 Genomes Project (1KGP), which underwent the same quality control  
182 process, we obtained a dataset containing 24,291 samples (Figure S1). To enhance data  
183 quality for ancestry inference, we conducted a filtering step to exclude variants exhibiting high  
184 levels of Linkage Disequilibrium (LD), using the command 'plink --indep-pairwise 100 10 0.1'.  
185 Additionally, variants located in regions known to be under recent selection were removed from  
186 the dataset<sup>53-55</sup>. We then ran ADMIXTURE using a total of 131,291 SNPs.

### 187 2.2.2 X Chromosome

188 After completing the general quality control steps described in section 2.2.1, we separated the  
189 variants on the X chromosome (coded as chromosome 23 in PLINK) from those in the  
190 pseudoautosomal regions (coded as chromosome 25 in PLINK). This separation was based  
191 on a dbSNP reference file. We also applied the XWAS cleaning pipeline (Figure 1)<sup>46</sup> for the X  
192 chromosome, which includes; (i) selecting the remaining individuals from the autosomal  
193 cleaning process, including samples without relatedness greater than second degree and  
194 samples with more than 75% of European ancestry, (ii) removal of SNPs following the same  
195 parameters used for the autosomes, besides SNPs with differential missingness between ASD  
196 individuals and controls with p-values lower than  $10^{-5}$ , (iii) removal of SNPs with differential  
197 missingness between males and females with p-values lower than  $10^{-5}$ , (v) heterozygous SNPs

198 found in males were assigned as missing data. For the XWAS logistic regression we used a  
199 final of 418,652 X chromosomal variants and 15,499 samples (Figure S1).

### 200 2.3. XWAS

201 After data cleaning, we conducted the XWAS analysis using two input files. The first file  
202 contained autosomal data with 1,075,065 variants, intended for principal component  
203 inferences to be used as covariates in the XWAS logistic regression. The second file consisted  
204 of X chromosome data with 418,652 variants. Both files contained data from the same 15,854  
205 samples. Among these samples, 9,550 were male (3,911 controls and 5,639 ASD individuals),  
206 and 6,304 were females (5,070 controls and 1,234 ASD individuals). The principal component  
207 inference was done with the GENESIS package stratified by sex (one PCA for males and one  
208 for females), where all samples with standard deviation greater than three from major clusters  
209 were defined as being outliers and removed from subsequent analyses. For the primary XWAS  
210 analysis, we utilized X chromosome data for principal component analysis (PCA). Additionally,  
211 we conducted a replication analysis using data from autosomal chromosomes. The resulting  
212 10 PCs from males only and females only were employed as covariates for Male-XWAS and  
213 Female-XWAS, respectively. Non-outlier males and females were merged to create both  
214 datasets. Subsequently, this new dataset underwent another PCA, where outliers were  
215 detected and excluded based on the same parameters. The 10 resulting PCs from this process  
216 were used as covariates in “Both-XWAS” (Figure 1).

217 The final regression analysis was performed using logistic regression in PLINK2<sup>56</sup> (--glm) for  
218 three approaches (Figure 1); (i) Male-XWAS: Based on 5,639 ASD male individuals and 3,911  
219 male controls. This approach used the 10 top PCs from males as covariates; (ii) Female-  
220 XWAS: Based on 1,234 ASD female individuals and 5,070 female controls. This approach  
221 used the 10 top PCs from females as covariates; and (iii) Both-XWAS: Based on 6,873 ASD  
222 individuals and 8,981 controls. This approach used the 10 top PCs from both and sex as  
223 covariates.

224 We also performed a meta-analysis from the sex-stratified results (Male-XWAS and Female-  
225 XWAS) implemented on GWAMA<sup>57,58</sup>. This result incorporates the "gender\_heterogeneity\_p-  
226 value," which is derived from assessing heterogeneity between sex-specific allelic effects. This  
227 result incorporates the "gender\_heterogeneity\_p-value," which is derived from assessing  
228 heterogeneity between sex-specific allelic effects using one degree of freedom. This test  
229 involved analyzing males and females separately in each XWAS. It entailed obtaining male-  
230 and female-specific allelic effect estimates in a fixed-effects meta-analysis, followed by testing  
231 for heterogeneity between the sexes<sup>58</sup>.

#### 232 *2.4 X-Chromosome Significance Threshold*

233 Given that our association tests are conducted on a single chromosome, the number of  
234 effective tests performed is lower compared to a genome-wide analysis. Typically, in genome-  
235 wide analyses, the significance threshold is set at p-value < 5x10<sup>-8</sup>. To determine an  
236 appropriate significance threshold for our XWAS analysis, we applied a Bonferroni correction  
237 by dividing 0.05 by the number of effective tests<sup>59</sup>.

238 The number of effective tests ( $N_{\text{eff}}$ ) was calculated by dividing the squared number of variants  
239 by the sum of the  $R^2$  correlation coefficients between all variants present in the dataset<sup>46</sup>:

$$240 \quad (N_{\text{eff}}) = V^2 / (\sum_{i=1}^V \sum_{j=1}^V L_{ij})$$

241  $V$  = Total number of variants

242  $L$  = the  $R^2$  correlation coefficient between all variants ( $V$ ) present in the datasets ( $L$  is a matrix  
243 with size  $V$  by  $V$ );  $i$  and  $j$  = Matrix indexes.

244 To generate the  $R^2$  matrix among all variants in our dataset, we utilized the command 'plink -  
245 -r2 square gz yes-really'. The sum of our corresponding matrix was: Female: 37441288.90;  
246 Male: 27721944.23 and Both: 53006792.62. Thus, the respective number of effective tests  
247 ( $N_{\text{eff}}$ ): Female:  $418,652^2 / 37441288.90 = 4,681.18$ ; Male:  $418,652^2 / 27721944.23 = 6,322.40$ ;

248 Both:  $418,652^2 / 53006792.62 = 3,306.54$  with the final significance threshold being; Female:  
249  $0.05 / 4,681.18 = 1.07 \times 10^{-5}$ ; Male:  $0.05 / 6,322.40 = 7.9 \times 10^{-6}$ ; Both:  $0.05 / 3,306.54 = 1.51 \times 10^{-5}$ .

## 250 2.5. *sdMAF*

251 Sex differences in allele frequencies were analyzed with the *sdMAF* software<sup>60,61</sup>. We initially  
252 split the pseudoautosomal regions (PAR) with the PLINK<sup>62</sup> `--split-par hg38` command. Since  
253 PLINK was not able to properly handle male homozygous in the bed file and simply assigned  
254 them all to missing, we bypassed the problem by changing the chromosome code to 22 prior  
255 to generating genotype counts. The chromosome number in the 'gcount' file was then re-coded  
256 back to 23 and subsequently pipelined into the *sdMAF* software as suggested by the *sdMAF*  
257 documentation<sup>61</sup>. To select the significant *sdMAF* results, we utilized the same conservative,  
258 Bonferroni-corrected significance level for XWAS-Both analysis ( $1.51 \times 10^{-5}$ ), given that we are  
259 testing the same number of SNPs.

## 260 2.6 *Rare variant analysis*

261 We further investigated the impact of rare genetic variations inside the candidate regions  
262 identified from the XWAS analysis by comparing the frequency of rare predicted damaging  
263 single nucleotide variants (SNVs; gnomAD frequency <0.1%), insertion and deletions smaller  
264 than 50bp (indels; gnomAD frequency <0.1%), and exonic copy number deletions (CNV  
265 deletions; gnomAD frequency <1%) impacting genes between ASD-probands and family  
266 members.

267 The initial reads were aligned to the GRCh38 human genome reference. Small variants (SNVs  
268 and Indels) and CNVs were called using GATK and *in-house* CNV calling pipeline,  
269 respectively<sup>63</sup>. Standard output files were generated, including CRAMs for alignment, and  
270 VCFs for small variants, and CNVs. Per sample analysis metrics were also generated. The  
271 small variant calls were annotated using an ANNOVAR-based pipeline<sup>64</sup>. Using an in-house  
272 script, we filtered high quality small variants that were found in less than 0.1% of gnomAD

273 samples. We then selected only damaging small variants if they result in a stop gain or a  
274 frameshift, or, they are nonsynonymous SNVs predicted to be damaging by four different in-  
275 silico tools (i.e.,  $\text{sift\_score}^{65} \leq 0.05$ ,  $\text{polyphen\_score}^{66} \geq 0.9$ ,  $\text{mt\_score}^{67} \geq 0.5$ , and  
276  $\text{CADD\_phred}^{68} \geq 15$ ). For this SNVs analysis, besides the WGS data previous described  
277 (session 2.1.1), we also used whole exome data (WES) from SPARK, given a final number of  
278 47,840 ASD-probands (79% males), 19,820 ASD-unaffected siblings (47% males), and 63,692  
279 ASD-parents (40% fathers).

280 The deletions were detected using a previously described read depth-based pipeline<sup>34,63</sup>. We  
281 only considered high-quality deletions, which were tagged based on the following criteria; (i)  
282 length  $\geq 5\text{kb}$ , ii. called by both ERDS<sup>69</sup> and CNVnator<sup>70</sup> with at least 50% reciprocally  
283 overlapped in length, (ii) having  $< 70\%$  of its length overlap with repetitive or low complexity  
284 regions of the genome (i.e., telomere, centromere, and segmental duplications), and (iii). for  
285 the X chromosomal calls in males, CNVs in PAR were filtered out. For the CNV comparison  
286 we only used WGS data, and we also included data from the new MSSNG release  
287 (MSSNGdb7), resulting in a total of 9,691 ASD-probands (82% males), 5,591 ASD-unaffected  
288 siblings (38% males) and 17,470 ASD-parents (50% fathers).

289 For both small variants and deletions, independently, we performed an association analysis  
290 using a conditional logistic regression stratifying the test by the family. For sex-combined  
291 analysis, we also used sex as covariates.

## 292 *2.7 Brain gene Expression Analysis*

293 Exon-averaged gene expression data were obtained from BrainSpan (Allen Brain Atlas)<sup>71</sup>. With  
294 this microarray data, we further applied quantile normalization and standardization across both  
295 genes and samples for the comparative analysis. Subsequently, we generated a brain map  
296 plot wherein colors ranging from blue (indicating downregulation) to red (indicating  
297 upregulation) denote the average expression levels of the selected genes within each brain  
298 region. This visualization was created for five developmental stages: Early Fetal (less than 16

299 weeks), Late Fetal (more than 16 weeks to birth), Early Childhood (birth to three years old),  
300 Childhood/Teenage (three years to 20 years), and Adulthood (more than 20 years).

### 301 **3. Results**

#### 302 3.1 Association Test


303 After performing the four different XWAS tests (Figure 1), which included sex-stratified tests  
304 (Male-XWAS and Female-XWAS), sex-combined mega-analysis (Both-XWAS), and meta-  
305 analysis (Meta-XWAS), we identified 59 variants as significant in at least one of the four  
306 approaches (Table S2). These variants correspond to a total of 20 risk loci, encompassing 23  
307 genes with variants in high linkage disequilibrium ( $r^2 > 0.7$ ) with the lead SNP (Table 1). The  
308 genomic loci detected from the four XWAS approaches utilized are shown in Table 1. Among  
309 these, 42 were found uniquely by a unitary XWAS approach: 27 in the Male-XWAS, five in the  
310 Female-XWAS, one in the Both-XWAS (performed with males and females together, using sex  
311 as a covariate), and nine in the Meta-XWAS (a meta-analysis of Male-XWAS and Female-  
312 XWAS results using GWAMA<sup>57</sup> software, because it includes a "meta-analysis using sex-  
313 differentiated and sex heterogeneity"<sup>57</sup>). Additionally, 17 variants showed significant p-values  
314 in more than one test (Table S2). Each test underwent visual inspection via histograms and  
315 QQ plots, revealing no distortions as indicated by the genomic inflation factor ( $\lambda=0.928 - 1.036$ ),  
316 which measures systematic bias in the statistical test (Figure S2, Figure 2). Among the 59  
317 variants, 30 exhibit a "gender heterogeneity p-value" (test for heterogeneity between sexes  
318 with one degree of freedom)<sup>58</sup> below 0.05, all of them in the sex stratified approaches (26 in  
319 the Male-XWAS and four in the Female-XWAS), suggesting significant differences in allelic  
320 effects between males and females for these variants. Notably, two of these variants, identified  
321 in the Male-XWAS within the *ASB11* gene, attained a "gender heterogeneity p-value" of less  
322 than  $9 \times 10^{-5}$ . In the presence of heterogeneity in allelic effects between the sexes, a loss of  
323 power for sex-combined association tests can occur if the allele has opposite direction of effect

324 in the other sex<sup>58</sup>. This type of biological phenomena may explain why variants are not detected  
 325 in Both-XWAS and Meta-XWAS.

326 **Table 1. Genomic Risk Loci.** Genomic loci detected from four XWAS analyses (Male-XWAS,  
 327 Female-XWAS, Both-XWAS, Meta-XWAS). The unique ID as well as the p-value refer to the  
 328 lead SNPs specified. The 23 genes in the last column are within the gene locus, and  
 329 encompass variants exhibiting strong linkage disequilibrium with the lead SNP ( $r^2 > 0.7$ ).

XWAS approach	Genomic Locus	UniqueID	Lead SNPs	p	start_hg37	end_hg37	start_hg38	end_hg38	Size_hg38	Genes
Males	1_Male-XWAS	23:15283903:A:C	rs12687599	3.57E-07	15274671	15366179	15256549	15348057	91508	ASB9, ASB11, PIGA
Males	2_Male-XWAS	23:89417731:C:T	rs148591304	1.09E-06	89417731	89426923	90162732	90171924	9192	Intergenic
Males	3_Male-XWAS	23:99660751:C:T	rs12835197	4.33E-06	99631253	99686238	100376255	100431240	54985	PCDH19
Female	1_Female-XWAS	23:16787511:C:T	rs185190849	1.68E-06	16683001	17354197	16664878	17336074	671196	TXLNG,CTPS2, REPS2
Female	2_Female-XWAS	23:113992014:A:G	rs191071511	9.58E-06	113958523	113992014	114724114	114757574	33460	HTR2C
Female	3_Female-XWAS	23:129957059:C:T	rs186814690	2.41E-06	129769645	130270300	130635671	131136326	500655	ENOX2
Both	1_Both-XWAS	23:19374946:C:T	rs767542284	2.61E-06	19215082	20143856	19196964	20125738	928774	PDHA1
Both	2_Both-XWAS	23:22885946:A:G	rs5926125	9.47E-06	22854092	22893611	22835975	22875494	39519	PTCHD1-AS
Both	3_Both-XWAS	23:71657264:A:G	rs5958792	1.85E-06	71657264	71657264	72437414	72437414	0	HDAC8
Both	4_Both-XWAS	23:89417731:C:T	rs148591304	5.69E-07	89417731	89426923	90162732	90171924	9192	Intergenic
Meta	1_Meta-XWAS	23:16522448:C:T	rs111827716	8.40E-06	16487766	16523991	16469643	16505868	36225	Intergenic
Meta	2_Meta-XWAS	23:20723519:A:G	rs776360992	6.15E-06	20723519	20748993	20705401	20730875	25474	LOC124905257
Meta	3_Meta-XWAS	23:22885946:A:G	rs5926125	7.30E-06	22854092	22893611	22835975	22875494	39519	PTCHD1-AS
Meta	4_Meta-XWAS	23:31460970:A:G	rs139802025	2.44E-06	31460970	31460970	31442853	31442853	0	DMD
Meta	5_Meta-XWAS	23:71623954:G:T	rs73218354	1.42E-07	71623954	72600433	72404104	73380597	976493	HDAC8, PABPC1L2A
Meta	6_Meta-XWAS	23:89417731:C:T	rs148591304	5.53E-07	89417731	91160501	90162732	91905502	1742770	PCDH11X
Meta	7_Meta-XWAS	23:99660751:C:T	rs12835197	4.87E-06	99631253	99686238	100376255	100431240	54985	PCDH19
Meta	8_Meta-XWAS	23:101756502:C:T	rs5945876	9.79E-06	101060265	101847597	101805292	102592669	787377	TCP11X3P, BEX5
Meta	9_Meta-XWAS	23:113958523:G:T	rs140894960	1.76E-06	113939197	114789771	114704781	115555444	850663	HTR2C
Meta	10_Meta-XWAS	23:129834346:A:G	rs189525731	3.40E-07	129223355	130791852	130089380	131657839	1568459	ENOX2

330



331

332 **Figure 2. ASD-XWAS manhattan and qq plots.** Each panel shows a Manhattan plot on the  
333 left part and qqPlot on the right part. The graphs result from XWAS testing using 6,873 ASD  
334 individuals (5,639 males and 1,234 females) and 8,981 controls (3,911 males and 5,070



335 females) with a total of 418,652 X chromosomal variants originated from WGS data (46  
336 variants in PAR regions) for (A) Male-XWAS, B) Female-XWAS, C) Both-XWAS, and D) the  
337 Meta-XWAS, a meta-analysis from the sex stratified approaches implemented on GWAMA<sup>57</sup>.

### 338 3.1.2 Robustness Study

339 We performed XWAS analyses using various configurations, including one ASD dataset  
340 against all controls, as well as all ASD against each control dataset, to mitigate potential bias  
341 stemming from dataset heterogeneity and to conduct robust sanity replications, (Table S3).  
342 Consequently, we obtained XWAS results for; (i) MSSNG as cases versus HostSeq and MGRB  
343 as controls, (ii) SSC as cases versus HostSeq and MGRB as controls, (iii) SPARK as cases  
344 versus HostSeq and MGRB as controls, (iv) MSSNG, SSC, and SPARK as cases versus  
345 HostSeq as controls, (v) MSSNG, SSC, and SPARK as cases versus MGRB as controls and  
346 (vi) control versus control (sanity test; MGRB was labeled as cases and HostSeq as control).

347 Among the 27 variants exclusively found in males, all replication tests yielded a p-value below  
348 0.05, except for eight variants solely in robustness test "v" (involving all case datasets versus  
349 MGRB controls). Notably, these eight variants reside within the first significant region identified  
350 in the Male-XWAS, spanning between 15.27 and 15.36 Mb. Even after excluding these eight  
351 variants, we retained 19 significant SNPs in this region with a p-value lower than 0.05 across  
352 all replication tests.

353 Regarding the five variants in the detected exclusive in Female-XWAS, two did not reach a p-  
354 value lower than 0.05 across all robustness tests. One of them, rs749183760 in *ENOX2*, was  
355 not captured by test "ii". Additionally, the intergenic SNP rs182249604, located within the first  
356 significant genomic region (between 16.7Mb and 17.33Mb), did not yield a p-value lower than  
357 0.05 on test "iii". However, even after excluding these variants, we still observe significant  
358 SNPs in this region, including variants within the *TXLN* gene.

359 Considering the results from the Both-XWAS replications, there is only one significant variant  
360 (rs767542284 in *PDHA1*), that also demonstrated a significant p-value in all subset (i-v)  
361 analyses; five of nine variants detected in the Meta-XWAS achieved significant p-values in all  
362 cohort tests, and these are located within *DMD*, *PABPC1L2A* and *PCDH11X*. When comparing  
363 the significant variants detected in both Meta-XWAS and Both-XWAS (8 variants located on  
364 *PTCHD1-AS*, *HDAC8*, and *LOC124905257* genes), we replicated five results across all cohort  
365 tests (i to v). Notably, the variants that did not reach a significant p-value in all tests include  
366 two variants in the *HDAC8* gene (rs5958792, rs73218354) and one intergenic variant  
367 (rs5981334), all of which were not replicated only in test "iii" (SPARK versus all control  
368 cohorts).

369 All six results identified in both the Female-XWAS and another XWAS (Meta-XWAS, Both-  
370 XWAS) were situated within two different genes, *ENOX2* and *HTR2C*. None of these variants  
371 achieved a p-value < 0.05 in test ii (SSC versus all controls). Three significant variants were  
372 detected in both the Male-XWAS and Meta-XWAS. All three variants had significant p-values  
373 in all tests except for one variant (rs12835197 - *PCDH19*) in test "v" (All cases versus MGRB).

374 We performed a sanity check employing logistic regression, where controls were compared  
375 against controls (Test "vi"), using MGRB as cases and Hostseq as controls. To fortify the  
376 reliability of our findings, we assessed whether our candidate variants yielded non-significant  
377 p-values ( $\geq 0.05$ ) in this sanity test as well. At least one variant in the genes *ASB9* and *ASB11*  
378 from Male-XWAS analysis meet the criteria of the sanity test. Hence, we retained both genes  
379 in the final results. In the Female-XWAS results, three out of the five detected variants failed  
380 to pass the sanity test, resulting in only the *ENOX2* gene being included among the final genes.

### 381 3.1.3 XWAS replication using Autosomal Principal Components as covariates

382 Our principal component analysis (PCA) focused solely on the X chromosome due to its unique  
383 biological features (see Methods section 2.3). Therefore, the top 10 PCs were then considered  
384 as covariates<sup>46</sup>. We also implemented XWAS with autosomal PCs to assess the


385 generalizability of findings (Table S4, Figure S3 and Figure S4). The modified model revealed  
386 a total of 58 significant loci spanning over 12 genes: *ASB9*, *ASB11*, *PIGA*, *PCDH19*, *TXLNG*,  
387 *HTR2C*, *ENOX2*, *PDHA1*, *PTCHD1-AS*, *DMD*, *HDAC8*, and *PABPC1L2A* (Table 2); 11 of  
388 these overlap with the genes detected by the primary analysis using X chromosome-only PCs  
389 (Figure S4). The *PIGA* gene was identified exclusively with the autosomal PC model, noting it  
390 is located in proximity to *ASB11*(3.8kb) and *ASB9* (48.9kb), which were detected in the Male-  
391 XWAS results using the X chromosome PCs. Among the 14 genes discovered by the XWAS  
392 using the X chromosome-only PCs only *X*, *LOC124905257* and *PCDH11X* were not present  
393 when using autosomal PCs in the XWAS.

394 The genomic control lambdas observed in the QQ plots ranged from 0.913 to 1.119 (Figure  
395 S4). Additionally, the correlation between the XWAS results obtained from X chromosome PCs  
396 and autosomal PCs was 0.76 for males and 0.79 for females (Figure S3). Overall, the results  
397 from the main analysis are generalizable and robust.

#### 398 3.1.4 Annotation

399 All XWAS results (Male-XWAS, Female-XWAS, Both-XWAS, Meta-XWAS) were annotated  
400 using both modules of FUMA<sup>72</sup>: SNP2GENE and GENE2FUNC. SNP2GENE mapped the  
401 genes corresponding to the significantly associated SNPs, while GENE2FUNC annotated  
402 gene expression and gene sets from the previously mapped genes. The 59 significant  
403 associated variants were mapped (within a 10kb distance) to a total of 93 genes (Table S5).  
404 Through the gene-based test conducted using MAGMA<sup>73</sup>, significant associations were  
405 identified for *ASB11* (p-value =  $2.87 \times 10^{-6}$ ) in the Male-XWAS (Figure 2, Figure 3-A), where  
406 initial SNPs were mapped to 704 genes given a significance threshold defined as  $7.1 \times 10^{-5}$   
407 (0.05/704). This gene was also mapped in the Female-XWAS analysis, being situated within  
408 at least 10kb distance from a significantly associated SNP. Notably, *ASB11* is located within  
409 one of the most significant Linkage Disequilibrium (LD) regions identified in the Male-XWAS  
410 results, spanning between 15.27 and 15.36Mb, which also encompasses the genes *ASB9* and

411 *PIGA* (Genomic Locus 1-Male-XWAS; Table 1). The corresponding LocusZoom plot, along  
412 with the Combined Annotation Dependent Depletion (CADD)<sup>68,74</sup> score and RegulomeDB  
413 score<sup>75,76</sup> plots for this region, are presented in Figure 3-A. The CADD score assesses the  
414 deleteriousness of genetic variants, while the RegulomeDB score evaluates their functional  
415 significance, aiding in the interpretation of their potential biological effects. When considering  
416 only significant SNPs falling internal to the gene rather than within a 10kb range, 13 candidates  
417 were identified: *ASB11*, *ASB9*, *DMD*, *ENOX2*, *HDAC8*, *HTR2C*, *LOC124905257*,  
418 *PABPC1L2A*, *PCDH11X*, *PCDH19*, *PDHA1*, *PTCHD1-AS* and *TXLNG* (Figure 2, Table 2).



419

420 **Figure 3. Annotation details for the genomic risk Locus 1\_Male-XWAS and 1\_Both**  
 421 **XWAS.** A) Details for the genomic risk locus *1\_Male-XWAS*. The upper panel shows the  
 422 LocusZoom plot for the correspondent region with the lead SNP rs12687599 highlighted in  
 423 purple. The used LD reference panel was Europeans from 1000G data<sup>77</sup> for both sexes


424 together. Following the LocusZoom plot, on the left, we provide annotation results displaying  
425 CADD and RegulomeDB scores. On the right, the Manhattan plot illustrates the gene-based  
426 test computed by MAGMA in FUMA. The SNPs were mapped to 704 protein-coding genes,  
427 hence the genome-wide significance threshold (indicated by the red dashed line in the plot)  
428 was conservatively set at  $P = 0.05/704 = 7.10 \times 10^{-5}$ . B) LocusZoom plot of the genomic locus  
429 *1\_Both-XWAS*, followed by the CADD and Regulome profiles of the same region.

430 In the sex-stratified analysis, the majority of the SNPs found to have significant association  
431 were located in intronic regions, accounting for 68.4% of the Male-XWAS results and 60% of  
432 the Female-XWAS results. Within the Both-XWAS results, 45.8% of the SNPs were intergenic,  
433 28.9% were non-coding RNAs, 22.9% were intronic, and an additional 2.4% located in UTR  
434 regions.

### 435 3.2 Sex differences in minor allele frequencies (sdMAF)

436 Evolutionary forces can influence allele frequency on the X chromosome between sexes  
437 compared to the autosomes<sup>78,79</sup>. To ensure the effectiveness of the quality control process,  
438 we have implemented sdMAF<sup>60,61</sup> analysis on the same set of genomic data. Subsequently,  
439 we removed all sdMAF significant results from the XWAS findings. These signals could be  
440 capturing either true biological sex differences or genotyping error, inducing spurious  
441 association between ASD and variants.

442 However, the sdMAF results also provided valuable insights. We applied sdMAF separately to  
443 ASD individuals and controls cohorts; and we observed scatters of statistically significant  
444 variants in both ASD individuals and controls (Figure 4). Single or few scatters were expected  
445 to be caused by genotyping error. The results from the region of *FGF13* gene was particularly  
446 prominent. Notably, *FGF13* is a previously ASD-associated gene with a SFARI score of 3S  
447 (Figure 4). Interestingly, the detection of this region is solely through sdMAF but not via logistic  
448 regressions, highlighting the potential of sdMAF being used as a tool for association studies of  
449 sex-biased diagnoses.



450

451 **Figure 4. sdMaf Results.** A) Left, the Manhattan plot illustrates the sdMAF p-values obtained  
452 from ASD datasets exclusively. Right, the Manhattan plot represents the sdMAF p-values  
453 obtained from control datasets only. B) The LocusZoom plot displays the region identified in  
454 the sdMAF-cases results, highlighting the gene *FGF13*. The LD reference panel used was  
455 Europeans from 1000G data<sup>77</sup> for both sexes together.

### 456 3.3 Rare variants analysis


457 Recognizing the significant role of rare variants in ASD genetic architecture<sup>34,80–83</sup>, we checked  
458 in the same ASD datasets (MSSNG, SSC and SPARK) for rare predicted damaging small  
459 variants (SNV/indels with less than 0.1% of frequency on gnomAD<sup>48</sup>) and CNV deletions (<1%  
460 frequency in gnomAD<sup>48</sup>) overlapping at least one exon of the 14 significant detected genes (13  
461 from XWAS and one from sdMAF).

462 Among the total of 14 XWAS genes analyzed (Figure 5), 11 exhibited rare predicted damaging  
463 SNVs. Among the remaining three genes, two were non-coding RNAs (LOC124905257 at  
464 HG38 chrX:20606477:20727481 and *PTCHD1-AS* at HG38 chrX:22193005:23293146), while  
465 the third was *PABPC1L2A* (HG38 chrX: 73077276:73079512). In the male frequency  
466 comparisons, almost all genes showed a higher frequency of these variants in ASD-probands

467 compared to other family members, except for *PCDH11X* and *PCDH19*. In females, five genes  
468 (*ASB11*, *DMD*, *HDAC8*, *PCDH19*, and *HTR2C*) showed a higher frequency in ASD-probands.  
469 Combining both sexes, four genes (*ASB11*, *DMD*, *HDAC8*, *HTR2C*, and *FGF13*) showed a  
470 higher frequency in ASD-probands.

471 We successfully identified rare deletions overlapping exons in the joint ASD datasets for the  
472 gene detected in sdMAF (*FGF13*) and for three of the 13 genes from the main XWAS results,  
473 including *PTCHD1-AS*, *DMD*, and *ENOX2* (Figure 5, Table 2). Comparing the frequency of  
474 these CNVs in unaffected family members, we observed an enrichment in cases compared to  
475 unaffected family members for deletions impacting *PTCHD1-AS* in males, *DMD* and *ENOX2*  
476 in females and both sexes combined, and *FGF13* in males and both sexes combined.  
477 However, none of the association test results reached a p-value lower than 0.05, but this might  
478 be expected because of sample size.





479

480 **Figure 5. Rare Variant Frequency Analysis.** The figure compares the frequencies of rare  
 481 variants among different groups: ASD-Probands (red bars), ASD-Unaffected Siblings (green  
 482 bars), and ASD-Parents (gray bars). The left panel shows the frequency of rare predicted  
 483 damaging SNVs (<0.1% frequency in general population) across 11 genes (*ASB9*, *ASB11*,  
 484 *TXLNG*, *PDHA1*, *PTCHD1-AS*, *DMD*, *HDAC8*, *PCDH11X*, *PCDH19*, *HTR2C*, *ENOX2*, *FGF13*)

485 detected through XWAS common variant data analysis (Table 2). The right panel illustrates  
486 the frequency of rare CNV deletions overlapping exons (< 1% frequency in general population),  
487 found in four XWAS-genes (*PTCHD1-AS*, *DMD*, *ENOX2*, *FGF13*). In each graph, the  
488 corresponding p-value from a conditional logistic regression is shown at the bottom, conducted  
489 separately for males, females, and both sexes combined (using “sex” as covariate).

#### 490 3.4 Brain Gene expression analysis


491 Utilizing data from BrainSpan (Allen Brain Atlas)<sup>71</sup>, we generated a visualization to examine  
492 the mean expression patterns of 12 of 14 candidate genes detected in our previous analysis  
493 across various brain regions during distinct developmental periods (Figure 6). Data for  
494 *LOC124905257* and *PTCHD1-AS* were not available in BrainSpan. In general, the ASD-XWAS  
495 candidate genes showed different expression levels in all different time ranges when compared  
496 with the plotted controls (Figure 6 last three columns).

497 During the early fetal stage, the 12 XWAS genes exhibit up-regulation in the cerebellum, which  
498 contrasts with the pattern observed in the Female-XWAS genes, showing notably low  
499 expression levels in the same region. In males, XWAS genes in the early fetal stage  
500 demonstrate down-regulated expression in the primary motor cortex and the primary visual  
501 cortex, alongside up-regulated expression in the prefrontal, primary somatosensory, and  
502 posteroventral parietal cortex. In this stage, the most expressed brain regions in Female-  
503 XWAS genes include the primary visual, primary auditory, and temporal cortex.

504 Transitioning to the late fetal stage, the most pronounced pattern includes down-regulated  
505 expression of Male-XWAS genes across nearly all analyzed brain regions. In contrast, All-  
506 XWAS genes exhibit heightened expression in the primary auditory, temporal, and prefrontal  
507 cortex. In early childhood, spanning the initial three years of life, a consistent down-regulated  
508 expression pattern is observed in the cerebellum across all approaches (All XWAS genes and  
509 sex-stratified comparisons). Furthermore, during this phase, the posteroventral parietal cortex  
510 displays elevated expression levels for All-XWAS genes.

511 From ages three to 20 (childhood to teenage years), X candidate genes remain downregulated  
512 in the cerebellum, while both sex-stratified approaches indicate up-regulation in the primary  
513 auditory and visual cortex. Additionally, the prefrontal cortex exhibits high expression levels for  
514 Male-XWAS genes.

515 In adulthood (after 20 years), the cerebellum maintains a down regulated pattern for all XWAS  
516 genes and for the genes identified in Male-XWAS, while exhibiting slightly higher expression  
517 levels in the genes identified in Female-XWAS. Conversely, the prefrontal cortex demonstrates  
518 low expression levels for the genes identified in Male-XWAS, with an upregulation pattern  
519 observed in the genes identified in Female-XWAS.



520

521 **Figure 6. Gene Expression by Brain Regions in different development times.** Brain map  
 522 showing the gene expression levels in different parts of the brain in five developmental stages  
 523 (Early Fetal, Late fetal, Early childhood, Childhood/Teenage and Adulthood). Left to right  
 524 shows the gene expression levels from all 12 ASD-candidate genes with available expression  
 525 data (*ASB11*, *ASB9*, *DMD*, *ENOX2*, *FGF13*, *HDAC8*, *HTR2C*, *PABPC1L2A*, *PCDH11X*,  
 526 *PCDH19*, *PDHA1*, *TXLNG*), followed by three genes from Male-XWAS (*ASB11*, *ASB9*,  
 527 *PCDH19*), three genes from Female-XWAS (*TXLNG*, *HTR2C*, *ENOX2*) and the correspondent  
 528 control comparison with all the ~800 X chromosome genes in both sexes and also in male

529 brains only and female brains only. The color scales go from blue (downregulated) to red  
530 (upregulated).

#### 531 **4. Discussion**

532 Our XWAS analyses identified 59 SNP variants on the X chromosome that exhibited a  
533 statistically significant association with ASD (Table S2). These variants were mapped to 91  
534 distinct genes, of which 11 had previously been associated with ASD through the detection of  
535 rare variants or CNVs, as reported in databases (Table S5). Out of the 59 significant variants  
536 identified in the main analysis, 35 were also successfully detected in our robustness study  
537 (Table S3), spanning all five different tests. Among these, 33 variants passed the sanity test  
538 by not reaching a significant value in the Control vs Control test “vi”. These 33 X-Chromosome  
539 variants were located in intergenic regions as well as in the genes *ASB9*, *ASB11*, *PDHA1*,  
540 *LOC124905257*, *PTCHD1-AS*, *HDAC8*, *PABPC1L2A*, and *PCDH11X* (Table 2). These new  
541 results will increase our understanding of the genes involved in ASD and provide a basis for  
542 improving polygenic risk scores (PRS), which currently are significantly underpowered  
543 regarding ASD<sup>34,84</sup>.

544 In the Male-XWAS results we detected an LD region encompassing the genes *ASB9*, *ASB11*  
545 and *PIGA*. The lead SNP, rs12687599, is reported in the GWAS catalog<sup>85</sup> for being associated  
546 with sex hormone-binding globulin levels<sup>86</sup>. Autism was previously associated with a  
547 decreased level of maternal serum sex hormone binding globulin<sup>87</sup>. This finding could imply an  
548 etiological association between sex hormone pathways and ASD status particularly in males  
549 <sup>16,23</sup>. Still in the Male-XWAS, we identified the gene *PCDH19*, also found in the Meta-XWAS.  
550 This gene has the highest significance score of 1 in the SFARI database, indicating its  
551 significant relevance to ASD<sup>26</sup>. It is also classified as syndromic, primarily expressed in brain  
552 tissue and plays a role in cell adhesion<sup>88</sup>, suggesting that mutations within it are associated  
553 with an increase in ASD likelihood and are consistently linked to neurodevelopmental and  
554 neuropsychiatric characteristics beyond those necessary for an ASD diagnosis.

555 The Both-XWAS and Meta-XWAS identified significantly associated variants in the lncRNA  
556 *PTCHD1-AS* (*PTCHD1* antisense RNA)<sup>89</sup>. This gene is part of a complex on chromosome  
557 Xp22.11, which also encompasses *DDX53*, placing this locus among the most prevalent and  
558 impactful genetic factors for ASD<sup>90</sup> and other neurodevelopmental disorders. Ross *et al.*,  
559 2021<sup>89</sup>, conducted an analysis compiling data from previously reported variants on *PTCHD1-*  
560 *AS*. They found that 69% of these variants associated with this long non-coding RNA (lncRNA)  
561 are linked to ASD or ASD-related features. Consequently, the EAGLE score, a metric  
562 evaluating a gene's relevance to ASD, definitively assigns *PTCHD1-AS* a final score of 17.6<sup>27</sup>.  
563 However, despite this association, the functional significance of these variants remains  
564 unknown.

565 In the Meta-XWAS we identified significant variants associated with ASD in *DMD* and *HDAC8*.  
566 Notably, *HDAC8* was also highlighted in the Both-XWAS results. Both genes carry a syndromic  
567 status on the SFARI gene score. Both *DMD* and *HDAC8* are linked to intellectual disability,  
568 with *DMD* additionally implicated in attention-deficit hyperactivity disorder (ADHD) and extra-  
569 pyramidal syndrome (EPS). The *DMD* gene was the only gene to reach a significant  
570 enrichment p-value (0.01) when comparing rare deletions in probands against unaffected  
571 family members specifically for females. This finding suggests a potential sex-specific effect of  
572 rare deletions in the *DMD* gene, with females exhibiting a significant enrichment compared to  
573 unaffected family members. Our previous genomic studies of CNVs<sup>34</sup> further support the  
574 importance of rare deletions in *DMD*.

575 We also applied a case-only sdMAF analysis in a complementary way to the traditional case-  
576 control association analysis. This analysis pointed out a significant peak overlapping *FGF13*<sup>91</sup>  
577 with variants in this gene being involved in infantile-onset developmental and epileptic  
578 encephalopathy, which can be important associated features of ASD.

579 In summary, our XWAS study of individuals with ASD and controls has generated significant  
580 new data that further validate the roles of specific genes in autism and unveil novel candidates

581 for future research. Our approach, utilizing XWAS 'common variant' analyses alongside  
 582 parallel 'rare variant' examinations of the same samples, provides a unique paradigm for  
 583 dissecting the genomic architecture involved in ASD and potentially other complex conditions.  
 584 Additionally, while the development of an X-chromosome-based Polygenic Risk Score (X-  
 585 PRS) is of interest, it is beyond the scope of this paper and may require new methodologies<sup>29</sup>.

586 **Table 2. Significantly associated ASD genes based on our main XWAS and sdMAF**  
 587 **results.** The values in red are the p-values considered significant based on the specific  
 588 Bonferroni corrections (Males:  $7.9 \times 10^{-6}$ , Females:  $1.07 \times 10^{-5}$ , Both:  $1.51 \times 10^{-5}$ ).

Gene	Dataset	LeadSNP	P_Meta	P_Males	P_Females	P_Both	Other Evidences
ASB9	Males	rs12687599	5.74E-04	<b>3.57E-07</b>	6.79E-01	5.56E-04	Robustness test, Replication using Autosomal PCs, rare variants detected
ASB11	Males	rs6628945	1.22E-03	<b>8.27E-07</b>	6.01E-01	1.12E-03	Robustness test, Replication using Autosomal PCs, rare variants detected
TXLNG	Females	rs753342681	1.31E-03	5.08E-01	<b>1.68E-06</b>	9.01E-03	Robustness test, Replication using Autosomal PCs, rare variants detected
PDHA1	Both	rs767542284	3.01E-05	7.93E-04	2.62E-03	<b>2.61E-06</b>	Robustness test, Replication using Autosomal PCs, rare variants detected
LOC124905257	Meta	rs776360992	<b>6.15E-06</b>	2.60E-05	5.11E-02	4.29E-05	Robustness test
PTCHD1-AS	Meta, Both	rs5926125	<b>7.30E-06</b>	1.89E-04	1.04E-02	9.47E-06	Trost; et al (2023), Autdb, SFARI 2, Robustness test, Replication using Autosomal PCs, rare variants detected
DMD	Meta	rs139802025	<b>2.44E-06</b>	8.35E-05	7.82E-03	5.33E-04	Trost; et al (2023), Autdb 3, SFARI S, Replication using Autosomal PCs, rare variants detected
HDAC8	Meta, Both	rs73218354	<b>1.42E-07</b>	8.14E-05	3.92E-04	<b>1.04E-05</b>	Trost; et al (2023), Autdb2, SFARI S, Robustness test, Replication using Autosomal PCs, rare variants detected
PABPC1L2A	Meta	rs115820229	<b>1.76E-06</b>	1.70E-04	3.09E-03	1.18E-04	Robustness test, Replication using Autosomal PCs
PCDH11X	Meta	rs184604300	<b>1.38E-05</b>	2.25E-04	2.12E-02	4.92E-03	Autdb2, SFARI 2, Robustness test, rare variants detected
PCDH19	Males, Meta	rs12835197	<b>4.87E-06</b>	<b>4.33E-06</b>	8.30E-02	3.94E-04	Autdb4, SFARI 1S, rare variants detected
HTR2C	Females, Meta	rs140894960	<b>1.76E-06</b>	7.01E-02	<b>9.58E-06</b>	3.95E-03	Replication using Autosomal PCs, rare variants detected
ENOX2	Females, Meta	rs186814690	<b>5.06E-07</b>	2.68E-02	<b>2.41E-06</b>	5.59E-05	CNVfreq, Replication using Autosomal PCs, rare variants detected
FGF13	sdMAF	rs555083289	sdMAF pvalue = <b>1.19E-05</b>				Autdb 2, SFARI 3S, rare variants detected

589

## 590 **Declaration of interests**

591 At the time of this study and its publication, S.W.S. served on the Scientific Advisory Committee  
592 of Population Bio. Intellectual property from aspects of his research held at The Hospital for  
593 Sick Children are licensed to Athena Diagnostics and Population Bio. These relationships did  
594 not influence data interpretation or presentation during this study but are disclosed for potential  
595 future considerations.

## 596 **Acknowledgments**

597 We thank the families participating in MSSNG, SSC, and SPARK, as well as the resources  
598 provided by Autism Speaks and The Centre for Applied Genomics. M.M.A was supported by  
599 the CGEn HostSeq/CIHR fellowship (CGE 185054) and the SickKids Restracom Fellowship.  
600 S.B.C was supported in part by the Intramural Research Program of the NIH and the National  
601 Institute on Aging (NIA). M.C.L is supported by a Canadian Institutes of Health Research Sex  
602 and Gender Science Chair (GSB 171373). S.W.S holds the Northbridge Chair in Pediatric  
603 Research at The Hospital for Sick Children and the University of Toronto.

## 604 **Web resources**

605 Approved researchers can obtain the MSSNG dataset by applying at <https://research.mss.ng/>;  
606 and the SSC and SPARK datasets at <https://base.sfari.org>. 1000 genomes data is publicly  
607 available at <https://www.internationalgenome.org/>, HostSeq data can be also available after  
608 applying at <https://www.cgen.ca/hostseq-databank-access-request> and MGRB genomic data  
609 is deposited at the European Genome-Phenome Archive under study ID EGAS00001003511.

## 610 **Author contributions**

611 Conceptualization: M.M.A, D.Z.C, T.P.L, L.S, S.W.S

612 Data curation: M.M.A, W.E, B.Thiruvahindrapuram, B.Trost, J.L.H, G.P, T.N



- 613 Formal Analysis: M.M.A, D.Z.C, W.E, E.A.M, S.B.C, D.R
- 614 Funding acquisition: S.W.S
- 615 Investigation: M.M.A, D.Z.C, W.E, B.Trost, , J.L.H, M.C.L, C.A.B, L.S, S.W.S
- 616 Methodology: M.M.A, D.Z.C, W.E, T.P.L, B.Thiruvahindrapuram, G.P, T.N, R.A, N.B.S, E.A.M,  
617 N.R.A, S.B.C, D.R
- 618 Project administration: J.L.H, L.S, S.W.S
- 619 Resources: S.W.S
- 620 Software: M.M.A, D.Z.C, T.P.L, L.S
- 621 Supervision: L.S, S.W.S
- 622 Validation: M.M.A, W.E, N.B.S, C.A.B
- 623 Visualization: M.M.A, W.E
- 624 Writing – original draft: M.M.A, W.E, B.Trost, M.C.L, L.S, S.W.S
- 625 Writing – review & editing: M.M.A, D.Z.C, W.E, T.P.L, B.Thiruvahindrapuram, B.Trost, J.L.H,  
626 G.P, T.N, R.A, N.B.S, E.A.M, N.R.A, M.C.L, S.B.C, D.R, C.A.B, L.S, S.W.S

627 **References**

- 628 1. Zeidan, J., Fombonne, E., Scolah, J., Ibrahim, A., Durkin, M.S., Saxena, S., Yusuf, A.,  
629 Shih, A., and Elsabbagh, M. (2022). Global prevalence of autism: A systematic review  
630 update. *Autism Res.* 15, 778–790. 10.1002/aur.2696
- 631 2. Lord, C., Elsabbagh, M., Baird, G., and Veenstra-Vanderweele, J. (2018). Autism  
632 spectrum disorder. *The Lancet* 392, 508–520. 10.1016/S0140-6736(18)31129-2
- 633 3. Loomes, R., Hull, L., and Mandy, W.P.L. (2017). What Is the Male-to-Female Ratio in  
634 Autism Spectrum Disorder? A Systematic Review and Meta-Analysis. *J. Am. Acad. Child*  
635 *Adolesc. Psychiatry* 56,.10.1016/j.jaac.2017.03.013
- 636 4. Maenner, M.J., Warren, Z., Williams, A.R., Amoakohene, E., Bakian, A.V., Bilder, D.A.,  
637 Durkin, M.S., Fitzgerald, R.T., Furnier, S.M., Hughes, M.M., et al. (2023). Prevalence and

- 638 Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and  
639 Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. *MMWR*  
640 *Surveill. Summ.* 72,. 10.15585/mmwr.ss7202a1
- 641 5. Lai, M.C., Lombardo, M.V., Auyeung, B., Chakrabarti, B., and Baron-Cohen, S. (2015).  
642 Sex/gender differences and autism: setting the scene for future research. *J. Am. Acad. Child*  
643 *Adolesc. Psychiatry* 54,.10.1016/j.jaac.2014.10.003
- 644 6. Jacquemont, S., Coe, B.P., Hersch, M., Duyzend, M.H., Krumm, N., Bergmann, S.,  
645 Beckmann, J.S., Rosenfeld, J.A., and Eichler, E.E. (2014). A higher mutational burden in  
646 females supports a “female protective model” in neurodevelopmental disorders. *Am. J. Hum.*  
647 *Genet.* 94, 415–425. 10.1016/j.ajhg.2014.02.001
- 648 7. Pinto, D., Delaby, E., Merico, D., Barbosa, M., Merikangas, A., Klei, L.,  
649 Thiruvahindrapuram, B., Xu, X., Ziman, R., Wang, Z., et al. (2014). Convergence of genes  
650 and cellular pathways dysregulated in autism spectrum disorders. *Am. J. Hum. Genet.* 94,  
651 677–694. 10.1016/j.ajhg.2014.03.018
- 652 8. Leow, K.Q., Tonta, M.A., Lu, J., Coleman, H.A., and Parkington, H.C. (2024). Towards  
653 understanding sex differences in autism spectrum disorders. *Brain Res.* 1833, 148877.  
654 10.1016/j.brainres.2024.148877
- 655 9. Palmer, N., Beam, A., Agniel, D., Eran, A., Manrai, A., Spettell, C., Steinberg, G., Mandl,  
656 K., Fox, K., Nelson, S.F., et al. (2017). Association of Sex With Recurrence of Autism  
657 Spectrum Disorder Among Siblings. *JAMA Pediatr.* 171, 1107–1112.  
658 10.1001/jamapediatrics.2017.2832
- 659 10. Napolitano, A., Schiavi, S., La Rosa, P., Rossi-Espagnet, M.C., Petrillo, S., Bottino, F.,  
660 Tagliente, E., Longo, D., Lupi, E., Casula, L., et al. (2022). Sex Differences in Autism  
661 Spectrum Disorder: Diagnostic, Neurobiological, and Behavioral Features. *Front. Psychiatry*  
662 13, 889636. 10.3389/fpsyt.2022.889636
- 663 11. Zhang, Y., Li, N., Li, C., Zhang, Z., Teng, H., Wang, Y., Zhao, T., Shi, L., Zhang, K., Xia,  
664 K., et al. (2020). Genetic evidence of gender difference in autism spectrum disorder supports  
665 the female-protective effect. *Transl. Psychiatry* 10, 4. 10.1038/s41398-020-0699-8
- 666 12. Antaki, D., Guevara, J., Maihofer, A.X., Klein, M., Gujral, M., Grove, J., Carey, C.E.,  
667 Hong, O., Arranz, M.J., Hervas, A., et al. (2022). A phenotypic spectrum of autism is  
668 attributable to the combined effects of rare variants, polygenic risk and sex. *Nat. Genet.* 54,.  
669 10.1038/s41588-022-01064-5
- 670 13. Warriar, V., Zhang, X., Reed, P., Havdahl, A., Moore, T.M., Cliquet, F., Leblond, C.S.,  
671 Rolland, T., Rosengren, A., Rowitch, D.H., et al. (2022). Genetic correlates of phenotypic  
672 heterogeneity in autism. *Nat. Genet.* 54,. 10.1038/s41588-022-01072-5
- 673 14. Wigdor, E.M., Weiner, D.J., Grove, J., Fu, J.M., Thompson, W.K., Carey, C.E., Baya, N.,  
674 van der Merwe, C., Walters, R.K., Satterstrom, F.K., et al. (2022). The female protective  
675 effect against autism spectrum disorder. *Cell Genomics* 2,. 10.1016/j.xgen.2022.100134
- 676 15. Elsabbagh, M. (2020). Linking risk factors and outcomes in autism spectrum disorder: is  
677 there evidence for resilience? *BMJ* 368, l6880. 10.1136/bmj.l6880
- 678 16. Werling, D.M. (2016). The role of sex-differential biology in risk for autism spectrum  
679 disorder. *Biol. Sex Differ.* 7,. 10.1186/s13293-016-0112-8
- 680 17. Dougherty, J.D., Marrus, N., Maloney, S.E., Yip, B., Sandin, S., Turner, T.N., Selmanovic,

- 681 D., Kroll, K.L., Gutmann, D.H., Constantino, J.N., et al. (2022). Can the “female protective  
682 effect” liability threshold model explain sex differences in autism spectrum disorder? *Neuron*  
683 *110*,. 10.1016/j.neuron.2022.06.020
- 684 18. Leppa, V.M., Kravitz, S.N., Martin, C.L., Andrieux, J., Le Caignec, C., Martin-Coignard,  
685 D., DyBuncio, C., Sanders, S.J., Lowe, J.K., Cantor, R.M., et al. (2016). Rare Inherited and  
686 De Novo CNVs Reveal Complex Contributions to ASD Risk in Multiplex Families. *Am. J.*  
687 *Hum. Genet.* *99*, 540–554. 10.1016/j.ajhg.2016.06.036
- 688 19. Han, J., Walters, J.T.R., Kirov, G., Pocklington, A., Escott-Price, V., Owen, M.J.,  
689 Holmans, P., O'Donovan, M.C., and Rees, E. (2016). Gender differences in CNV burden do  
690 not confound schizophrenia CNV associations. *Sci. Rep.* *6*, 25986. 10.1038/srep25986
- 691 20. Martin, J., Tammimies, K., Karlsson, R., Lu, Y., Larsson, H., Lichtenstein, P., and  
692 Magnusson, P.K.E. (2019). Copy number variation and neuropsychiatric problems in females  
693 and males in the general population. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* *180*,  
694 341–350. 10.1002/ajmg.b.32685
- 695 21. Mitra, I., Tsang, K., Ladd-Acosta, C., Croen, L.A., Aldinger, K.A., Hendren, R.L., Traglia,  
696 M., Lavillaureix, A., Zaitlen, N., Oldham, M.C., et al. (2016). Pleiotropic Mechanisms  
697 Indicated for Sex Differences in Autism. *PLoS Genet.* *12*, e1006425.  
698 10.1371/journal.pgen.1006425
- 699 22. McCarthy, M.M. (2020). A new view of sexual differentiation of mammalian brain. *J.*  
700 *Comp. Physiol. A Neuroethol. Sens. Neural Behav. Physiol.* *206*, 369–378. 10.1007/s00359-  
701 019-01376-8
- 702 23. Amestoy, A., Baudrillard, C., Briot, K., Pizano, A., Bouvard, M., and Lai, M.C. (2023).  
703 Steroid hormone pathways, vitamin D and autism: a systematic review. *J. Neural Transm.*  
704 *130*,. 10.1007/s00702-022-02582-6
- 705 24. Lenz, K.M., Wright, C.L., Martin, R.C., and McCarthy, M.M. (2011). Prostaglandin E<sub>2</sub>  
706 regulates AMPA receptor phosphorylation and promotes membrane insertion in preoptic area  
707 neurons and glia during sexual differentiation. *PLoS One* *6*, e18500.  
708 10.1371/journal.pone.0018500
- 709 25. VanRyzin, J.W., Marquardt, A.E., Argue, K.J., Vecchiarelli, H.A., Ashton, S.E., Arambula,  
710 S.E., Hill, M.N., and McCarthy, M.M. (2019). Microglial Phagocytosis of Newborn Cells Is  
711 Induced by Endocannabinoids and Sculptures Sex Differences in Juvenile Rat Social Play.  
712 *Neuron* *102*, 435–449.e6. 10.1016/j.neuron.2019.02.006
- 713 26. Abrahams, B.S., Arking, D.E., Campbell, D.B., Mefford, H.C., Morrow, E.M., Weiss, L.A.,  
714 Menashe, I., Wadkins, T., Banerjee-Basu, S., and Packer, A. (2013). SFARI Gene 2.0: a  
715 community-driven knowledgebase for the autism spectrum disorders (ASDs). *Mol. Autism* *4*,  
716 36. 10.1186/2040-2392-4-36
- 717 27. Schaaf, C.P., Betancur, C., Yuen, R.K.C., Parr, J.R., Skuse, D.H., Gallagher, L., Bernier,  
718 R.A., Buchanan, J.A., Buxbaum, J.D., Chen, C.-A., et al. (2020). A framework for an  
719 evidence-based gene list relevant to autism spectrum disorder. *Nat. Rev. Genet.* *21*, 367–  
720 376. 10.1038/s41576-020-0231-2
- 721 28. Hoang, N., Buchanan, J.A., and Scherer, S.W. (2018). Heterogeneity in clinical  
722 sequencing tests marketed for autism spectrum disorders. *Npj Genomic Medicine* *3*, 1–4.  
723 10.1038/s41525-018-0066-3

- 724 29. Sun, L., Wang, Z., Lu, T., Manolio, T. A., & Paterson, A. D. (2023). eXclusionaryY: 10  
725 years later, where are the sex chromosomes in GWASs?. *American journal of human*  
726 *genetics*, 110(6), 903–912. [10.1016/j.ajhg.2023.04.009](https://doi.org/10.1016/j.ajhg.2023.04.009)
- 727 30. Chung, R.-H., Ma, D., Wang, K., Hedges, D.J., Jaworski, J.M., Gilbert, J.R., Cuccaro,  
728 M.L., Wright, H.H., Abramson, R.K., Konidari, I., et al. (2011). An X chromosome-wide  
729 association study in autism families identifies TBL1X as a novel autism spectrum disorder  
730 candidate gene in males. *Mol. Autism* 2, 18. [10.1186/2040-2392-2-18](https://doi.org/10.1186/2040-2392-2-18)
- 731 31. Gottipati, S., Arbiza, L., Siepel, A., Clark, A.G., and Keinan, A. (2011). Analyses of X-  
732 linked and autosomal genetic variation in population-scale whole genome sequencing. *Nat.*  
733 *Genet.* 43, 741–743. [10.1038/ng.877](https://doi.org/10.1038/ng.877)
- 734 32. Le Guen, Y., Napolioni, V., Belloy, M.E., Yu, E., Krohn, L., Ruskey, J.A., Gan-Or, Z.,  
735 Kennedy, G., Eger, S.J., and Greicius, M.D. (2021). Common X-Chromosome Variants Are  
736 Associated with Parkinson Disease Risk. *Ann. Neurol.* 90, 22–34. [10.1002/ana.26051](https://doi.org/10.1002/ana.26051)
- 737 33. Gao, F., Chang, D., Biddanda, A., Ma, L., Guo, Y., Zhou, Z., and Keinan, A. (2015).  
738 XWAS: A Software Toolset for Genetic Data Analysis and Association Studies of the X  
739 Chromosome. *J. Hered.* 106, 666–671. [10.1093/jhered/esv059](https://doi.org/10.1093/jhered/esv059)
- 740 34. Trost, B., Thiruvahindrapuram, B., Chan, A. J. S., Engchuan, W., Higginbotham, E. J.,  
741 Howe, J. L., Loureiro, L. O., Reuter, M. S., Roshandel, D., Whitney, J., Zarrei, M., Bookman,  
742 M., Somerville, C., Shaath, R., Abdi, M., Aliyev, E., Patel, R. V., Nalpathamkalam, T.,  
743 Pellecchia, G., Hamdan, O., ... Scherer, S. W. (2022). Genomic architecture of autism from  
744 comprehensive whole-genome sequence annotation. *Cell*, 185(23), 4409–4427. [e18.](https://doi.org/10.1016/j.cell.2022.10.009)  
745 <https://doi.org/10.1016/j.cell.2022.10.009>
- 746 35. C Yuen, R.K., Merico, D., Bookman, M., L Howe, J., Thiruvahindrapuram, B., Patel, R.V.,  
747 Whitney, J., Deflaux, N., Bingham, J., Wang, Z., et al. (2017). Whole genome sequencing  
748 resource identifies 18 new candidate genes for autism spectrum disorder. *Nat. Neurosci.* 20,  
749 602–611. [10.1038/nn.4524](https://doi.org/10.1038/nn.4524)
- 750 36. Black, D.W., and Jon E. Grant, M.D., M.P.H., J.D. (2014). DSM-5 Guidebook: The  
751 Essential Companion to the Diagnostic and Statistical Manual of Mental Disorders, Fifth  
752 Edition (American Psychiatric Pub).
- 753 37. Lord, C., Rutter, M., and Le Couteur, A. (1994). Autism Diagnostic Interview-Revised: A  
754 revised version of a diagnostic interview for caregivers of individuals with possible pervasive  
755 developmental disorders. *J. Autism Dev. Disord.* 24, 659–685. [10.1007/BF02172145](https://doi.org/10.1007/BF02172145)
- 756 38. Kim, S.H., and Lord, C. (2011). New Autism Diagnostic Interview-Revised Algorithms for  
757 Toddlers and Young Preschoolers from 12 to 47 Months of Age. *J. Autism Dev. Disord.* 42,  
758 82–93. [10.1007/s10803-011-1213-1](https://doi.org/10.1007/s10803-011-1213-1)
- 759 39. Lord, C., Rutter, M., Goode, S., Heemsbergen, J., Jordan, H., Mawhood, L., and  
760 Schopler, E. (1989). Autism diagnostic observation schedule: A standardized observation of  
761 communicative and social behavior. *J. Autism Dev. Disord.* 19, 185–212.  
762 [10.1007/BF02211841](https://doi.org/10.1007/BF02211841)
- 763 40. Lord, C., Risi, S., Lambrecht, L., Cook, E.H., Jr, Leventhal, B.L., DiLavore, P.C., Pickles,  
764 A., and Rutter, M. (2000). The autism diagnostic observation schedule-generic: a standard  
765 measure of social and communication deficits associated with the spectrum of autism. *J.*  
766 *Autism Dev. Disord.* 30, 205–223.

- 767 41. Fischbach, G. D., & Lord, C. (2010). The Simons Simplex Collection: a resource for  
768 identification of autism genetic risk factors. *Neuron*, 68(2), 192–195.  
769 <https://doi.org/10.1016/j.neuron.2010.10.006>
- 770 42. SPARK Consortium. Electronic address: [pfeliciano@simonsfoundation.org](mailto:pfeliciano@simonsfoundation.org), & SPARK  
771 Consortium (2018). SPARK: A US Cohort of 50,000 Families to Accelerate Autism Research.  
772 *Neuron*, 97(3), 488–493. <https://doi.org/10.1016/j.neuron.2018.01.015>
- 773 43. Byrska-Bishop, M., Evani, U.S., Zhao, X., Basile, A.O., Abel, H.J., Regier, A.A., Corvelo,  
774 A., Clarke, W.E., Musunuri, R., Nagulapalli, K., et al. (2022). High-coverage whole-genome  
775 sequencing of the expanded 1000 Genomes Project cohort including 602 trios. *Cell* 185,  
776 3426–3440.e19. [10.1016/j.cell.2022.08.004](https://doi.org/10.1016/j.cell.2022.08.004)
- 777 44. Pinese, M., Lacaze, P., Rath, E.M., Stone, A., Brion, M.-J., Ameer, A., Nagpal, S.,  
778 Puttick, C., Husson, S., Degraeve, D., et al. (2020). The Medical Genome Reference Bank  
779 contains whole genome and phenotype data of 2570 healthy elderly. *Nat. Commun.* 11, 1–  
780 14. [10.1038/s41467-019-14079-0](https://doi.org/10.1038/s41467-019-14079-0)
- 781 45. Yoo, S., Garg, E., Elliott, L.T., Hung, R.J., Halevy, A.R., Brooks, J.D., Bull, S.B., Gagnon,  
782 F., Greenwood, C.M.T., Lawless, J.F., et al. (2023). HostSeq: A Canadian Whole Genome  
783 Sequencing and Clinical Data Resource.
- 784 46. Leal, T.P., French-Kwawu, J.N., Gouveia, M.H., Borda, V., Inca-Martinez, M., Mason,  
785 E.A., Horimoto, A.R., Loesch, D.P., Sarihan, E.I., Cornejo-Olivas, M.R., et al. (2023). X-  
786 Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson  
787 Disease. [10.1002/mds.29508](https://doi.org/10.1002/mds.29508)
- 788 47. Franke, L., de Kovel, C.G.F., Aulchenko, Y.S., Trynka, G., Zhernakova, A., Hunt, K.A.,  
789 Blauw, H.M., van den Berg, L.H., Ophoff, R., Deloukas, P., et al. (2008). Detection,  
790 imputation, and association analysis of small deletions and null alleles on oligonucleotide  
791 arrays. *Am. J. Hum. Genet.* 82, 1316–1333. [10.1016/j.ajhg.2008.05.008](https://doi.org/10.1016/j.ajhg.2008.05.008)
- 792 48. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins,  
793 R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint  
794 spectrum quantified from variation in 141,456 humans. *Nature* 581, 434–443.  
795 [10.1038/s41586-020-2308-7](https://doi.org/10.1038/s41586-020-2308-7)
- 796 49. Manichaikul, A., Mychaleckyj, J.C., Rich, S.S., Daly, K., Sale, M., and Chen, W.-M.  
797 (2010). Robust relationship inference in genome-wide association studies. *Bioinformatics* 26,  
798 2867–2873. [10.1093/bioinformatics/btq559](https://doi.org/10.1093/bioinformatics/btq559)
- 799 50. Leal, T.P., Furlan, V.C., Gouveia, M.H., Saraiva Duarte, J.M., Fonseca, P.A., Tou, R.,  
800 Scliar, M. de O., Araujo, G.S. de, Costa, L.F., Zolini, C., et al. (2022). NAToRA, a  
801 relatedness-pruning method to minimize the loss of dataset size in genetic and omics  
802 analyses. *Comput. Struct. Biotechnol. J.* 20, 1821–1828. [10.1016/j.csbj.2022.04.009](https://doi.org/10.1016/j.csbj.2022.04.009)
- 803 51. Alexander, D.H., Novembre, J., and Lange, K. (2009). Fast model-based estimation of  
804 ancestry in unrelated individuals. *Genome Res.* 19, 1655–1664. [10.1101/gr.094052.109](https://doi.org/10.1101/gr.094052.109)
- 805 52. Fairley, S., Lowy-Gallego, E., Perry, E., and Flicek, P. (2019). The International Genome  
806 Sample Resource (IGSR) collection of open human genomic variation resources. *Nucleic  
807 Acids Res.* 48, D941–D947. [10.1093/nar/gkz836](https://doi.org/10.1093/nar/gkz836)
- 808 53. Price, A.L., Weale, M.E., Patterson, N., Myers, S.R., Need, A.C., Shianna, K.V., Ge, D.,  
809 Rotter, J.I., Torres, E., Taylor, K.D., et al. (2008). Long-range LD can confound genome

- 810 scans in admixed populations. *Am. J. Hum. Genet.* **83**, 132–135; author reply 135–139.  
811 [10.1016/j.ajhg.2008.06.005](https://doi.org/10.1016/j.ajhg.2008.06.005)
- 812 54. Weale, M.E. (2010). Quality control for genome-wide association studies. *Methods Mol.*  
813 *Biol.* **628**, 341–372. [10.1007/978-1-60327-367-1\\_19](https://doi.org/10.1007/978-1-60327-367-1_19)
- 814 55. Anderson, C.A., Pettersson, F.H., Clarke, G.M., Cardon, L.R., Morris, A.P., and  
815 Zondervan, K.T. (2010). Data quality control in genetic case-control association studies. *Nat.*  
816 *Protoc.* **5**, 1564–1573. [10.1038/nprot.2010.116](https://doi.org/10.1038/nprot.2010.116)
- 817 56. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015).  
818 Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience*  
819 **4**, 7. [10.1186/s13742-015-0047-8](https://doi.org/10.1186/s13742-015-0047-8)
- 820 57. Mägi, R., and Morris, A.P. (2010). GWAMA: software for genome-wide association meta-  
821 analysis. *BMC Bioinformatics* **11**, 1–6. [10.1186/1471-2105-11-288](https://doi.org/10.1186/1471-2105-11-288)
- 822 58. Magi, R., Lindgren, C.M., and Morris, A.P. (2010). Meta-analysis of sex-specific genome-  
823 wide association studies. *Genet. Epidemiol.* **34**, 846–853. [10.1002/gepi.20540](https://doi.org/10.1002/gepi.20540)
- 824 59. Bretherton, C.S., Widmann, M., Dymnikov, V.P., Wallace, J.M., and Bladé, I. (1999). The  
825 Effective Number of Spatial Degrees of Freedom of a Time-Varying Field. *J. Clim.* **12**, 1990–  
826 2009.
- 827 60. Chen, D.Z., Roshandel, D., Wang, Z., Sun, L., and Paterson, A.D. (2023).  
828 Comprehensive whole-genome analyses of the UK Biobank reveal significant sex differences  
829 in both genotype missingness and allele frequency on the X chromosome. *Hum. Mol. Genet.*  
830 **32**, ddad201. [10.1093/hmg/ddad201](https://doi.org/10.1093/hmg/ddad201)
- 831 61. Wang, Z., Sun, L., and Paterson, A.D. (2022). Major sex differences in allele frequencies  
832 for X chromosomal variants in both the 1000 Genomes Project and gnomAD. *PLoS Genet.*  
833 **18**, e1010231. [10.1371/journal.pgen.1010231](https://doi.org/10.1371/journal.pgen.1010231)
- 834 62. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D., Maller,  
835 J., Sklar, P., de Bakker, P.I.W., Daly, M.J., et al. (2007). PLINK: a tool set for whole-genome  
836 association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575.  
837 [10.1086/519795](https://doi.org/10.1086/519795)
- 838 63. Trost, B., Walker, S., Wang, Z., Thiruvahindrapuram, B., MacDonald, J. R., Sung, W. W.  
839 L., Pereira, S. L., Whitney, J., Chan, A. J. S., Pellicchia, G., Reuter, M. S., Lok, S., Yuen, R.  
840 K. C., Marshall, C. R., Merico, D., & Scherer, S. W. (2018). A Comprehensive Workflow for  
841 Read Depth-Based Identification of Copy-Number Variation from Whole-Genome Sequence  
842 Data. *American journal of human genetics*, **102**(1), 142–155.  
843 <https://doi.org/10.1016/j.ajhg.2017.12.007>
- 844 64. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of  
845 genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164.  
846 [10.1093/nar/gkq603](https://doi.org/10.1093/nar/gkq603)
- 847 65. Ng, P.C., and Henikoff, S. (2003). SIFT: Predicting amino acid changes that affect protein  
848 function. *Nucleic Acids Res.* **31**, 3812–3814. [10.1093/nar/gkg509](https://doi.org/10.1093/nar/gkg509)
- 849 66. Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P.,  
850 Kondrashov, A.S., and Sunyaev, S.R. (2010). A method and server for predicting damaging  
851 missense mutations. *Nat. Methods* **7**, 248–249. [10.1038/nmeth0410-248](https://doi.org/10.1038/nmeth0410-248)

- 852 67. Schwarz, J.M., Cooper, D.N., Schuelke, M., and Seelow, D. (2014). MutationTaster2:  
853 mutation prediction for the deep-sequencing age. *Nat. Methods* *11*, 361–362.  
854 10.1038/nmeth.2890
- 855 68. Kircher, M., Witten, D.M., Jain, P., O’Roak, B.J., Cooper, G.M., and Shendure, J. (2014).  
856 A general framework for estimating the relative pathogenicity of human genetic variants. *Nat.*  
857 *Genet.* *46*, 310–315. 10.1038/ng.2892
- 858 69. Zhu, M., Need, A.C., Han, Y., Ge, D., Maia, J.M., Zhu, Q., Heinzen, E.L., Cirulli, E.T.,  
859 Pelak, K., He, M., et al. (2012). Using ERDS to infer copy-number variants in high-coverage  
860 genomes. *Am. J. Hum. Genet.* *91*, 408–421. 10.1016/j.ajhg.2012.07.004
- 861 70. Abyzov, A., Urban, A.E., Snyder, M., and Gerstein, M. (2011). CNVnator: an approach to  
862 discover, genotype, and characterize typical and atypical CNVs from family and population  
863 genome sequencing. *Genome Res.* *21*, 974–984. 10.1101/gr.114876.110
- 864 71. Kang, H.J., Kawasawa, Y.I., Cheng, F., Zhu, Y., Xu, X., Li, M., Sousa, A.M.M., Pletikos,  
865 M., Meyer, K.A., Sedmak, G., et al. (2011). Spatio-temporal transcriptome of the human  
866 brain. *Nature* *478*, 483–489. 10.1038/nature10523
- 867 72. Watanabe, K., Taskesen, E., and van Bochoven, A. (2017). Functional mapping and  
868 annotation of genetic associations with FUMA. *Nat. Commun.* *8*, 1–11. 10.1038/s41467-017-  
869 01261-5
- 870 73. de Leeuw, C.A., Mooij, J.M., and Heskes, T. (2015). MAGMA: Generalized Gene-Set  
871 Analysis of GWAS Data. *PLoS Comput. Biol.* *11*, e1004219. 10.1371/journal.pcbi.1004219
- 872 74. Schubach, M., Maass, T., Nazaretyan, L., Röner, S., and Kircher, M. (2024). CADD v1.7:  
873 using protein language models, regulatory CNNs and other nucleotide-level scores to  
874 improve genome-wide variant predictions. *Nucleic Acids Res.* *52*, D1143–D1154.  
875 10.1093/nar/gkad989
- 876 75. Dong, S., Zhao, N., Spragins, E., Kagda, M.S., Li, M., Assis, P., Jolanki, O., Luo, Y.,  
877 Cherry, J.M., Boyle, A.P., et al. (2023). Annotating and prioritizing human non-coding  
878 variants with RegulomeDB v.2. *Nat. Genet.* *55*, 724–726. 10.1038/s41588-023-01365-3
- 879 76. Boyle, A.P., Hong, E.L., Hariharan, M., Cheng, Y., Schaub, M.A., Kasowski, M.,  
880 Karczewski, K.J., Park, J., Hitz, B.C., Weng, S., et al. (2012). Annotation of functional  
881 variation in personal genomes using RegulomeDB. *Genome Res.* *22*, 1790–1797.  
882 10.1101/gr.137323.112
- 883 77. 1000 Genomes Project Consortium, Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E.  
884 P., Kang, H. M., Korb, J. O., Marchini, J. L., McCarthy, S., McVean, G. A., & Abecasis, G.  
885 R. (2015). A global reference for human genetic variation. *Nature*, 526(7571), 68–74.  
886 <https://doi.org/10.1038/nature15393>
- 887 78. Day, F.R., Loh, P.-R., Scott, R.A., Ong, K.K., and Perry, J.R.B. (2016). A Robust  
888 Example of Collider Bias in a Genetic Association Study. *Am. J. Hum. Genet.* *98*, 392–393.  
889 10.1016/j.ajhg.2015.12.019
- 890 79. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., and Reich, D.  
891 (2006). Principal components analysis corrects for stratification in genome-wide association  
892 studies. *Nat. Genet.* *38*, 904–909. 10.1038/ng1847
- 893 80. Zarrei, M., Burton, C.L., Engchuan, W., Young, E.J., Higginbotham, E.J., MacDonald,  
894 J.R., Trost, B., Chan, A.J.S., Walker, S., Lamoureux, S., et al. (2019). A large data resource

- 895 of genomic copy number variation across neurodevelopmental disorders. *NPJ Genomic*  
896 *Medicine* 4,. 10.1038/s41525-019-0098-3
- 897 81. D'Abate, L., Walker, S., Yuen, R.K.C., Tammimies, K., Buchanan, J.A., Davies, R.W.,  
898 Thiruvahindrapuram, B., Wei, J., Brian, J., Bryson, S.E., et al. (2019). Predictive impact of  
899 rare genomic copy number variations in siblings of individuals with autism spectrum  
900 disorders. *Nat. Commun.* 10,. 10.1038/s41467-019-13380-2
- 901 82. Woodbury-Smith, M., Zarrei, M., Wei, J., Thiruvahindrapuram, B., O'Connor, I., Paterson,  
902 A.D., Yuen, R.K.C., Dastan, J., Stavropoulos, D.J., Howe, J.L., et al. (2020). Segregating  
903 patterns of copy number variations in extended autism spectrum disorder (ASD) pedigrees.  
904 *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 183,. 10.1002/ajmg.b.32785
- 905 83. Zarrei, M., Burton, C.L., Engchuan, W., Higginbotham, E.J., Wei, J., Shaikh, S., Roslin,  
906 N.M., MacDonald, J.R., Pellecchia, G., Nalpathamkalam, T., et al. (2023). Gene copy number  
907 variation and pediatric mental health/neurodevelopment in a general population. *Hum. Mol.*  
908 *Genet.* 32,. 10.1093/hmg/ddad074
- 909 84. Grove, J., Ripke, S., Als, T.D., Mattheisen, M., Walters, R.K., Won, H., Pallesen, J.,  
910 Agerbo, E., Andreassen, O.A., Anney, R., et al. (2019). Identification of common genetic risk  
911 variants for autism spectrum disorder. *Nat. Genet.* 51, 431–444. 10.1038/s41588-019-0344-8
- 912 85. Sollis, E., Mosaku, A., Abid, A., Buniello, A., Cerezo, M., Gil, L., Groza, T., Güneş, O.,  
913 Hall, P., Hayhurst, J., et al. (2023). The NHGRI-EBI GWAS Catalog: knowledgebase and  
914 deposition resource. *Nucleic Acids Res.* 51, D977–D985. 10.1093/nar/gkac1010
- 915 86. Ruth, K.S., Day, F.R., Tyrrell, J., Thompson, D.J., Wood, A.R., Mahajan, A., Beaumont,  
916 R.N., Wittemans, L., Martin, S., Busch, A.S., et al. (2020). Using human genetics to  
917 understand the disease impacts of testosterone in men and women. *Nat. Med.* 26, 252–258.  
918 10.1038/s41591-020-0751-5
- 919 87. Bilder, D.A., Worsham, W., Sullivan, S., Sean Esplin, M., Burghardt, P., Fraser, A., and  
920 Bakian, A.V. (2023). Sex-specific and sex-independent steroid-related biomarkers in early  
921 second trimester maternal serum associated with autism. *Mol. Autism* 14,. 10.1186/s13229-  
922 023-00562-5
- 923 88. Piton, A., Gauthier, J., Hamdan, F.F., Lafrenière, R.G., Yang, Y., Henrion, E., Laurent, S.,  
924 Noreau, A., Thibodeau, P., Karemera, L., et al. (2011). Systematic resequencing of X-  
925 chromosome synaptic genes in autism spectrum disorder and schizophrenia. *Mol. Psychiatry*  
926 16, 867. 10.1038/mp.2010.54
- 927 89. Joel Ross, P., Zhang, W.-B., Mok, R.S.F., Zaslavsky, K., Deneault, E., D'Abate, L.,  
928 Rodrigues, D.C., Yuen, R.K.C., Faheem, M., Mufteev, M., et al. (2020). Synaptic dysfunction  
929 in human neurons with autism-associated deletions in PTCHD1-AS. *Biol. Psychiatry* 87, 139.  
930 10.1016/j.biopsych.2019.07.014
- 931 90. Scala, M., Bradley, C.A., Howe, J.L., Trost, B., Salazar, N.B., Shum, C., Reuter, M.S.,  
932 MacDonald, J.R., Ko, S.Y., Frankland, P.W., et al. (2023). Genetic variants in contribute to  
933 Autism Spectrum Disorder associated with the Xp22.11 locus. medRxiv.  
934 10.1101/2023.12.21.23300383
- 935 91. Fry, A. E., Marra, C., Derrick, A. V., Pickrell, W. O., Higgins, A. T., Te Water Naude, J.,  
936 McClatchey, M. A., Davies, S. J., Metcalfe, K. A., Tan, H. J., Mohanraj, R., Avula, S., Williams,  
937 D., Brady, L. I., Mesterman, R., Tarnopolsky, M. A., Zhang, Y., Yang, Y., Wang, X., Genomics  
938 England Research Consortium, ... Chung, S. K. (2021). Missense variants in the N-terminal



939 domain of the A isoform of FHF2/FGF13 cause an X-linked developmental and epileptic  
940 encephalopathy. American journal of human genetics, 108(1), 176–185.  
941 <https://doi.org/10.1016/j.ajhg.2020.10.017>